The US FDA's approval of Valeant Pharmaceuticals International Inc.'s psoriasis treatment Siliq (brodalumab) comes with several of the strict safeguards, including a restrictive Risk Evaluation and Mitigation Strategy (REMS), discussed at the drug's July advisory committee meeting.
Because of observed cases of suicidal ideation and behavior in clinical trials with brodalumab, the drug will only be available...





